Trizepatide

Trizepatide (tirzepatide) is described as a dual GLP-1/GIP receptor agonist designed to improve both glycemic control and weight outcomes. The protocol explains that GLP-1 and GIP co-activation increases glucose-dependent insulin secretion while suppressing glucagon, which improves blood sugar control with lower hypoglycemia risk compared with non–glucose-dependent agents. At the same time, it slows gastric emptying and increases satiety through central appetite regulation, helping reduce caloric intake. The page highlights that GIP activity may add synergy beyond GLP-1 agonism alone, contributing to strong weight-loss results in trials. Pharmacokinetically, a roughly 5-day half-life supports weekly dosing and consistent receptor engagement. Overall, the mechanism is presented as combining endocrine glucose regulation with appetite and gastric-emptying effects to produce meaningful improvements in HbA1c and body weight when titrated carefully.